Liposomal amphotericin B (LAmB) combined wither either micafungin or deferasirox was synergistic in previous murine studies with mucormycosis or aspergillosis.
We hypothesized that triple therapy using LAmB, micafungin, and deferasirox could further improve outcomes of mucormycosis or aspergillosis.
Triple therapy improved survival and reduced tissue fungal burden of mice with mucormycosis and to a lesser extent with aspergillosis.
Continued investigation into the use of triple therapy against mucormycosis and aspergillosis is warranted.
2011-03-22
Eng.
Antimicrobial agents and chemotherapy
Los Angeles Biomedical Research Institute, Division of Infectious Diseases, Harbor-UCLA Medical Center, 1124 West Carson St., St. John's Cardiovascular Research Center, Torrance, CA 90502, USA. ibrahim [at] labiomed.org
Antimicrob Agents Chemother. 2011 Apr;55(4):1768-70
© Galenicom 1999-2013